Shionogi & Co., Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial ReportiCD ResearchFebruary 6, 2012 38 Pages - SKU: ICDR6792363 |
| Synopsis ICD Research's Shionogi & Co., Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report contains in depth information and data about the company and its operations. The profile contains a company overview, business description, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company. Summary ICD Research's Shionogi & Co., Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report is a crucial resource for industry executives and anyone looking to access key information about Shionogi & Co., Ltd.. ICD Research's Shionogi & Co., Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Scope
Shionogi & Co., Ltd. (Shionogi) is principally focused on the manufacture of pharmaceutical products, diagnostics, and other related products in the fields of circulation, metabolism, infection, immunity and cancer pain. Shionogi, along with 17 subsidiaries and four affiliates, is into the research, development, manufacturing, and marketing activities, with a principal focus on prescription drugs, OTC drugs and diagnostics. The company focuses on three therapeutic areas, metabolic syndrome, infectious diseases and pain. It sells vitamin compounds under POPON brand, cold remedies under PYLON brand, and denture products under CORRECT brand. Shionogi operates in Japan, North America and Europe. Shionogi is headquartered in Osaka, Japan. |
Related Markets
Pharmaceuticals Company Reports
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2012
- Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics
- Partnerships, Licensing, Investments and M&A Deals and Trends for March 2012 in Pharmaceuticals
- Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs

